Citations 8

Pulmonary Arterial Hypertension in Octogenarians: The Pulmonary Hypertension Association Registry

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A2150-A2150

10.1164/ajrccm.2025.211.abstracts.a2150

Abstract Rationale: Since the initial descriptions of pulmonary arterial hypertension (PAH), there has been a significant increase in PAH diagnoses among the geriatric population. Studies suggest that older PAH patients exhibit unique hemodynamic profiles and treatment responses. We hypothesized that patients ≥80 years old would have a unique clinical profile and worse outcomes. Methods: The Pulmonary Hypertension Association Registry (PHAR) is a prospective cohort of PAH and chronic thromboembolic pulmonary hypertension (CTEPH) patients new to care at a Pulmonary Hypertension Care Center in the US. Individuals <18 years of age and those with CTEPH were excluded. Clinical data, quality of life measures, and functional capacity were recorded at time of enrollment and at follow up visits. Octogenarians were defined as those ≥80 years old and non-octogenarians as <80 years old. Associations between age subgroups with the change in six-minute walk distance (6MWD), and worsened WHO functional class (WHO FC) at the next visit, and time to all-cause mortality were assessed using linear, binomial, and Cox regression, respectively. Results: The study sample included 87 PAH octogenarian patients and 2,583 non-octogenarian patients at enrollment. The Table shows that octogenarian PAH patients were of similar sex and race distribution as others, but had lower body mass index. Octogenarians were more likely to have idiopathic or CTD-related PAH, and differed from younger patients in terms of several sociodemographic variables. PAH treatment, WHO FC, quality of life, and hemodynamic also differed between the groups. Octogenarians had a lower change in 6MWD (-26m, 95%CI -52 – -2, p = 0.066) and worse WHO FC (2.0, 95%CI 1.1 – 3.8, p = 0.038) over time compared to other adults after adjustment for sex, BMI, PAH etiology, annual income, marital status, right atrial pressure, mean pulmonary artery pressure, and PAH treatment. Octogenarians had an increased risk of death compared to younger adults (hazard ratio 1.7, 95%CI 1.1 – 2.6, p = 0.022) after adjustment for covariates. Conclusions: While the eldest PAH patients may have some comparable features to younger patients, they are different in a variety of socioeconomic variables, disease type, hemodynamics, and number of PAH therapies. The eldest PAH patients demonstrate worse exercise and functional capacity with time and a 70% increased risk of death compared to younger patients. Further studies are needed to better characterize PAH in the elderly, as this may lead to more effective treatments and enhanced quality of life.
Review of Portopulmonary Hypertension Prevalence at Mayo Clinic in Arizona, Florida, and Minnesota

C63. THINKING OUTSIDE THE BOX: NEW INSIGHTS INTO SUBGROUPS OF PULMONARY HYPERTENSION | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A5532-A5532

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5532

Dexmedetomidine as a Potential Cause of Central Sleep Apnea

C63. SLEEP GEMS: CASE REPORTS FROM THE WORLD OF SLEEP MEDICINE | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A4596-A4596

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4596

Association Between Submaximal Exercise Gas Exchange and Clinical Worsening Events in Patients with Pulmonary Arterial Hypertension

B106. UNION SQUARE: OBSERVATIONAL STUDIES AND CLINICAL TRIALS IN PULMONARY HYPERTENSION | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A3602-A3602

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3602

The Utility of Serial Right Heart Catheterizations in Patients with Model for End Stage Liver Disease Exceptions for Portopulmonary Hypertension

TP82. TP082 LET IT BE - CLINICAL ADVANCES IN PULMONARY VASCULAR DISEASE: PAH AND BEYOND | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A3589-A3589

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3589

Tumor Emboli: A Rare Cause of Pulmonary Hypertension

B54. PULMONARY HYPERTENSION ASSOCIATED WITH DRUGS; CANCER THERAPIES AND OTHER UNUSUAL DISEASES: CLINICAL STUDIES AND CASE REPORT | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A3762-A3762

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3762

Quality of Life of Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Idiopathic Pulmonary Arterial Hypertension (IPAH): The Pulmonary Hypertension Association Registry (PHAR)

C104. LATEST CLINICAL INVESTIGATIONS IN ACUTE AND CHRONIC THROMBOEMBOLISM DISORDERS OF THE PULMONARY CIRCULATION | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6048-A6048

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6048

Successful Delivery of a Large Metastatic Uterine Leiomyosarcoma from the Lung

A70. UNUSUAL PRESENTATIONS AND MIMICS: WHAT YOU SEE IS NOT ALWAYS WHAT YOU GET | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A2288-A2288

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2288